한문장이 너무 길어요 해석좀ㅠ-엔토영어

The Indianapolis Business Journal leads off with Lechleiter's prediction that Amyvid, a groundbreaking new approach to diagnosing Alzheimer's which Lilly acquired recently, will get a regulatory nod in the U.S. in a matter of months. Dow Jones, meanwhile, zeroes in on Lechleiter's prediction that once Cymbalta faces generic competition in 2013, Lilly will be poised for growth again.